

Types of Trials Included in Trial Search Results

The search results table lists the trials that match your search criteria, as well as additional criteria, including a trial processing status. This status reflects the work of the Clinical Trials Reporting Office (CTRO). The CTRO reviews each trial submitted to the system in order to validate submitted information. During the validation process, the reviewers check for duplicate records and ensure that the submitter has provided all required information. CTRO does one of the following as part of the validation process, before abstraction:

- If all data is complete and accurate, the reviewers assign the trial the status "Accepted," and the system notifies the submitter by email.
- If information is missing, or there are discrepancies in the information provided, the reviewers can place a trial on hold. The CTRO contacts the submitter for clarification and/or to request missing documents, and resumes processing once the trial is validated.
- If the trial is a duplicate (i.e., another user has submitted the same trial), the reviewers assign the trial the status "Rejected," and the system sends the submitter an email message indicating the status and reason for the rejection. Reviewers may also reject a trial if CTEP/DCP/CCR has approved the trial. NCI transfers these trials internally.



If you have questions about a rejected trial, contact the CTRO at ncictro@mail.nih.gov. For more information about this process, refer to [Typical Life Cycle of a Trial](#) and [Amendment Process Life Cycle](#).

The search results table lists the trials that match your search criteria, as well as the following criteria:

- Processing status of the trial at the time of the search. For a definition of each status, refer to [Trial Processing Statuses](#).
 - **Submitted** - Submitter has registered original trial but CTRO has not validated it yet.
 - **Amendment Submitted** - Submitter has submitted amendment but CTRO has not validated it yet.
 - **Accepted** - Trial has passed validation.
 - **Rejected** - Trial did not pass validation. The search results table does not list these trials.
 - **Abstracted** - CTRO has abstracted the trial.
 - **Verification Pending** - CTRO has abstracted the trial and has sent the Trial Summary Report (TSR) to the trial submitter for abstraction verification.
 - **Abstraction Verified Response** - Submitter has verified the abstraction as per the TSR, and has returned feedback to the CTRO within five business days after receiving the TSR.
 - **Abstraction Verified No Response** - Submitter has not responded or returned verification feedback to the CTRO within five business days after receiving the TSR.
- User's role with respect to the trial. User roles include the following:
 - **Site Administrator** - Has full access to the trials led by the organization (plays lead organization role).
 - **Trial Submitter/Owner** - Has full access to the trials they own or submitted.
 - **Other user** - Any user other than the trial submitter, owner, or trial's lead organization system administrator.
- **Trial ownership.** Trial ownership types are as follows:
 - **Private trials** - Trials submitted or owned by the user who is currently logged in to Registration.
 - **Public trials** - Trials submitted by other registered users.

(A business day is any weekday that is not a Federal holiday. For a list of Federal holidays, refer to the U.S. Office of Personnel Management's list of [Federal Holidays](#).)



The search results table does not list Private trials with a processing status of Rejected nor Public trials with a processing status of Submitted or Rejected.

Clinical Trials Search Results

Show 10

Search:
Choose columns
<< < 1 > >>

NCI Trial Identifier	Title	Current Trial Status	Lead Organization	Lead Org Trial Identifier	Principal Investigator
NCI-2014-00260	A Phase II Open-Label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-Resistant Prostate Cancer	Active	Duke University Medical Center	Pro00046383	George
NCI-2012-02535	Parallel Phase II Trials of ZD1839 (Iressa®) Alone or Weekly Carboplatin and Paclitaxel followed by ZD1839 (Iressa®) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients ≥65 Years of Age	Complete	North Central Cancer Treatment Group	N0222	Jatoi, Ar
NCI-2012-01641	Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma	Temporarily Closed to Accrual	Southwest Oncology Group	S1107	Twardo
NCI-2011-02670	A Phase III Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD	Active	Children's Oncology Group	AAML1031	Aplenc,
NCI-2009-01104	Genome-Wide Association Study (GWAS) for Modifiers of Breast Cancer Risk in BRCA2 Mutation Carriers: Breast Cancer Protective Alleles by Whole Genome Association and Copy Number Analysis	Active	Gynecologic Oncology Group	GOG-8010	Greene

Showing 1 to 5 of 5 (filtered from 7,711 total entries)
<< < 1 > >>

Export options: CSV | Excel

To navigate the search results table, see [Working with Tables and Search Results](#).